Day 2Thursday, 24 April 2025 - CT (China Time, GMT+08:00)

Location: Pudong Ballroom 1-3

Kickstart Day Two with an electrifying live pitch competition featuring some of the most innovative biotech startups today. A select group of rising companies will take the stage to present their breakthrough ideas to the ChinaBio® Partnering Forum audience and a panel of esteemed judges.

The winner will receive a complimentary ticket to a future EBD Group event, along with exciting prizes to be announced! Don’t miss this opportunity to witness the next wave of biotech innovation in action.

Location: Pudong Ballroom 1-3

In a competitive biotech environment, newly formed companies (Newcos) have the potential to disrupt the landscape with innovative solutions, but they also face unique challenges in securing investment and achieving growth. This panel will bring together investors, biotech executives, and industry experts to discuss how Newcos can strategically position themselves to attract attention and capitalize on opportunities within the global and Chinese biotech ecosystems.

• What differentiates successful Newcos from the rest, and how can they craft compelling value propositions that resonate with investors across various regions, including China, APAC, and beyond?

• Exploring the essential elements of a strong foundation for Newcos, including partnerships, talent acquisition, and technology platforms that can drive long-term success.

• Insights into how Newcos can tailor their strategies to align with specific market conditions in different parts of the world, focusing on China's rapidly evolving biotech landscape.

Location: Pudong Ballroom 1-3

Join us for an illuminating fireside chat with the CEO of Ascentage Pharma, a trailblazing Chinese biotech company that has recently made history as the first pre-revenue biotech firm to achieve dual listing on both the Hong Kong Stock Exchange and the US stock market. This session will delve into Ascentage's groundbreaking journey, exploring the challenges and opportunities in the evolving landscape of global biotech investments, and discussing the implications of this milestone for the future of Chinese biotech on the international stage.

• Gain insights into Ascentage Pharma's historic dual listing on Hong Kong and US stock exchanges, marking the first pre-revenue Chinese biotech to achieve this milestone

• Explore the strategic decisions behind the first US biotech IPO of 2025, raising $126 million in a challenging market environment

• Cross-Border Momentum: The evolving landscape of fundraising, licensing, and market access.

• Understand how China’s biotech ecosystem is shaping global partnerships and investments.

Location: Pudong Ballroom 1-3

This panel will delve into how the convergence of AI and big data is reshaping the landscape of drug discovery and development, offering unprecedented opportunities for efficiency and innovation. Industry experts, data scientists, and biotech leaders will discuss how these technologies are not only transforming traditional research methodologies but also addressing challenges in experimental data reliability and integration into broader innovation strategies. The conversation will focus on the implications for accelerating drug development, cost reduction, and fostering collaboration among global firms.

• How are AI and big data fundamentally changing drug discovery processes, and what competitive advantages do they provide in speeding up R&D in China and globally?

• What are the critical challenges in ensuring the reliability of experimental data for AI model training as companies leverage AI for rapid drug design? How can addressing these challenges enhance cost reduction across the drug development lifecycle, and which specific areas within drug development are particularly suited for applied AI to maximize efficiency?